OTCMKTS:BETRF BetterLife Pharma (BETRF) Stock Forecast, Price & News $0.06 +0.00 (+7.41%) (As of 05:17 PM ET) Add Compare Share Share Today's Range$0.06▼$0.0650-Day Range$0.05▼$0.0752-Week Range$0.03▼$0.19Volume35,003 shsAverage Volume34,226 shsMarket Capitalization$5.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestProfileChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort Interest About BetterLife Pharma (OTCMKTS:BETRF) StockBetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of neurological disorders in Canada and internationally. It is involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's pipeline products include BETR-001 for the treatment of major depressive disorder, treatment resistance depression, cluster headaches, and post-traumatic stress disorder; and BETR-002 to treat benzodiazepine dependency, anxiety, and spasticity. It is also developing MM-003 for treatment of COVID-19 and other respiratory viral infections; MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia; and AP-002 for the treatment of cancer. BetterLife Pharma Inc. has a research agreement with the University of California San Diego for preclinical behavioral pharmacology studies of TD-0148A, a lysergic acid diethylamide derivative solution. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.Read More Receive BETRF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BetterLife Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BETRF Stock News HeadlinesJune 8, 2023 | finance.yahoo.comBetterLife Continues Progress on BETR-001 IND-Enabling StudiesApril 25, 2023 | finance.yahoo.comBetterLife To Present BETR-001 Preclinical Data at the 2023 Annual Meeting of the Society of Biological Psychiatry (SOBP) in San Diego, CaliforniaJune 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.April 24, 2023 | finance.yahoo.comBetterLife Pharma to Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceApril 20, 2023 | finance.yahoo.comBetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor ConferenceMarch 29, 2023 | proactiveinvestors.comBetterLife Pharma says BETR-001 drug candidate featured in Drug Discovery & Development articleMarch 29, 2023 | finance.yahoo.comBetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Drug Discovery & Development ArticleMarch 28, 2023 | americanbankingnews.comShort Interest in BetterLife Pharma Inc. (OTCMKTS:BETRF) Decreases By 43.5%June 9, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.March 22, 2023 | finance.yahoo.comPromise of BetterLife's Non-hallucinogenic LSD (BETR-001) For Treating Mood Disorders Highlighted in Medical Xpress ArticleMarch 14, 2023 | finance.yahoo.comCORRECTION -- BetterLife Closes $1,857,143 of Private PlacementMarch 14, 2023 | finance.yahoo.comBetterLife Closes $1,857,143 of Private PlacementMarch 13, 2023 | msn.comPsyched: Next-Gen Compounds For Depression, Congress, Rescheduling, Benzinga Psychedelics Conference & MoreMarch 10, 2023 | finance.yahoo.comBetterLife Files Amended and Restated Offering Document for Offering of UnitsMarch 9, 2023 | msn.comMood Disorders Could Get An Alternative Treatment With This Next-Gen, Non-Hallucinogenic PsychedelicMarch 9, 2023 | proactiveinvestors.comBetterlife Pharma's reports positive study findings for lead candidate BETR-001March 9, 2023 | finance.yahoo.comBetterlife Publishes Promising Results from a Study Titled “A Non-Hallucinogenic LSD Analog With Therapeutic Potential For Mood Disorders”March 8, 2023 | finance.yahoo.comBetterLife Announces Pricing of Proposed Offering of UnitsMarch 7, 2023 | finance.yahoo.comBetterLife Announces Offering of UnitsJanuary 26, 2023 | proactiveinvestors.comBetterLife Pharma hires strategic advisory services firm to support development toward clinical trials of its psychedelic compoundsJanuary 26, 2023 | finance.yahoo.comBetterLife Announces Engagement of Bloom Burton Securities Inc. and Provides Summary of 2022 AccomplishmentsDecember 7, 2022 | proactiveinvestors.comBetterLife Pharma closes private placement with help from Negev Capital to fuel clinical programsDecember 2, 2022 | proactiveinvestors.comBetterLife to present BETR-001 preclinical data at the American College of Neuropsychopharmacology meeting in PhoenixDecember 2, 2022 | finance.yahoo.comBetterLife To Present BETR-001 Preclinical Data at the 61ST Annual Meeting of the American College of Neuropsychopharmacology (ACNP) in Phoenix, ArizonaSeptember 27, 2022 | msn.comPsychedelics Companies And IPs: An Extended Patent Application To Protect Multiple LSD DerivativesSeptember 27, 2022 | proactiveinvestors.comBetterLife Pharma files comprehensive patent for BETR-001 and other LSD derivativesSeptember 27, 2022 | finance.yahoo.comBetterLife Files Comprehensive Patent for BETR-001 and Other LSD DerivativesSee More Headlines BETRF Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BETRF Company Calendar Today6/09/2023Fiscal Year End1/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:BETRF CUSIPN/A CIK1464165 Webwww.abetterlifepharma.com Phone604-221-0595FaxN/AEmployees7Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-6,900,000.00 Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-3,686.46% Debt Debt-to-Equity RatioN/A Current Ratio0.01 Quick Ratio0.01 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($0.07) per share Price / Book-0.83Miscellaneous Outstanding Shares85,400,000Free Float55,707,000Market Cap$4.95 million OptionableNot Optionable Beta1.50 Key ExecutivesDr. Ahmad Doroudian Ph.D. (Age 63)Founder, CEO & Chairman Comp: $300kMs. Moira Ong C.A. (Age 48)CPA, CA, CFA, Chief Financial Officer Comp: $264kDr. Hooshmand Sheshbaradaran Ph.D. (Age 55)Chief Operating Officer Comp: $341.37kMr. Scott Rudge Ph.D.Head of CMCAnthony Calandra Ph.D.Head of RegulatoryDr. Abdi Ghaffari Ph.D.Head of Preclinical & ToxicologyMore ExecutivesKey Competitors180 Life SciencesNASDAQ:ATNFPainReformNASDAQ:PRFXHelix BioMedixOTCMKTS:HXBMXenetic BiosciencesNASDAQ:XBIOEvoke PharmaNASDAQ:EVOKView All Competitors BETRF Stock - Frequently Asked Questions How have BETRF shares performed in 2023? BetterLife Pharma's stock was trading at $0.1216 at the beginning of 2023. Since then, BETRF shares have decreased by 52.3% and is now trading at $0.0580. View the best growth stocks for 2023 here. What is BetterLife Pharma's stock symbol? BetterLife Pharma trades on the OTCMKTS under the ticker symbol "BETRF." How do I buy shares of BetterLife Pharma? Shares of BETRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is BetterLife Pharma's stock price today? One share of BETRF stock can currently be purchased for approximately $0.06. How much money does BetterLife Pharma make? BetterLife Pharma (OTCMKTS:BETRF) has a market capitalization of $4.95 million. The company earns $-6,900,000.00 in net income (profit) each year or ($0.08) on an earnings per share basis. How can I contact BetterLife Pharma? BetterLife Pharma's mailing address is 1275 WEST 6TH AVENUE, VANCOUVER A1, V6H 1A6. The official website for the company is www.abetterlifepharma.com. The company can be reached via phone at 604-221-0595 or via email at ir@blifepharma.com. This page (OTCMKTS:BETRF) was last updated on 6/9/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BetterLife Pharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.